Evaluation of intestinal permeability by triple sugar test in patients with autoimmune liver diseases

D. Akberova, A. K. Odintsоva, D. Abdulganieva
{"title":"Evaluation of intestinal permeability by triple sugar test in patients with autoimmune liver diseases","authors":"D. Akberova, A. K. Odintsоva, D. Abdulganieva","doi":"10.32000/2072-1757-2023-3-48-54","DOIUrl":null,"url":null,"abstract":"We evaluated intestinal permeability by triple sugar test in patients with autoimmune liver diseases. Patients were divided into groups with autoimmune hepatitis, primary biliary cholangitis and overlap syndrome (autoimmune hepatitis/primary biliary cholangitis). 102 people were included in the cross-sectional study: 72 patients with autoimmune liver diseases and 30 healthy volunteers. Diagnose based on recommendations — EASL (2017), AASLD (2019), IAIHG (2021). Small intestine permeability was evaluated by the ratio of lactulose/mannitol in urine, large bowel permeability by the level of sucralose in urine (nmol/l). We used the method of high-performance liquid chromatography–mass spectrometry. Patients with autoimmune liver diseases had increased small intestine permeability – 0.12 [0.07; 0.234] (p < 0.001) compared to the control group — 0.013 [0.01; 0.025]. Large bowel permeability — 760.8 [386.4; 1640] nmol/l did not differ from group control — 785.6 [408; 1027.2]. Increased small intestine permeabilityin patients with autoimmune liver diseases: stage of hepatitis — 0.17 [0.118; 0.253] (p < 0.001), liver cirrhosis — 0.106 [0.07; 0.23] (p < 0.001) compared with the control group. Large bowel permeability in patients with hepatitis and in liver cirrhosis did not differ from control group. Increased values of the triple sugar test were detected in patients with autoimmune hepatitis (increased permeability of the small intestine (0,09 [0,07; 0,17] (p < 0.05), increased permeability of large bowel — 1091,2 [760; 2352] (p < 0.05)) and overlap syndrome (increased small intestine permeability — 0.18 [0,086; 0,3] (p < 0,05) and increased large bowel permeability — 880 [424; 1680] (p < 0,05)) at the stage of liver cirrhosis. Patients with autoimmune liver diseases show the increased permeability of the small intestine. The presence of increased permeability of the small and large intestine may indicate the progression of the disease.","PeriodicalId":9821,"journal":{"name":"中国实用医药","volume":"17 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实用医药","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32000/2072-1757-2023-3-48-54","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

We evaluated intestinal permeability by triple sugar test in patients with autoimmune liver diseases. Patients were divided into groups with autoimmune hepatitis, primary biliary cholangitis and overlap syndrome (autoimmune hepatitis/primary biliary cholangitis). 102 people were included in the cross-sectional study: 72 patients with autoimmune liver diseases and 30 healthy volunteers. Diagnose based on recommendations — EASL (2017), AASLD (2019), IAIHG (2021). Small intestine permeability was evaluated by the ratio of lactulose/mannitol in urine, large bowel permeability by the level of sucralose in urine (nmol/l). We used the method of high-performance liquid chromatography–mass spectrometry. Patients with autoimmune liver diseases had increased small intestine permeability – 0.12 [0.07; 0.234] (p < 0.001) compared to the control group — 0.013 [0.01; 0.025]. Large bowel permeability — 760.8 [386.4; 1640] nmol/l did not differ from group control — 785.6 [408; 1027.2]. Increased small intestine permeabilityin patients with autoimmune liver diseases: stage of hepatitis — 0.17 [0.118; 0.253] (p < 0.001), liver cirrhosis — 0.106 [0.07; 0.23] (p < 0.001) compared with the control group. Large bowel permeability in patients with hepatitis and in liver cirrhosis did not differ from control group. Increased values of the triple sugar test were detected in patients with autoimmune hepatitis (increased permeability of the small intestine (0,09 [0,07; 0,17] (p < 0.05), increased permeability of large bowel — 1091,2 [760; 2352] (p < 0.05)) and overlap syndrome (increased small intestine permeability — 0.18 [0,086; 0,3] (p < 0,05) and increased large bowel permeability — 880 [424; 1680] (p < 0,05)) at the stage of liver cirrhosis. Patients with autoimmune liver diseases show the increased permeability of the small intestine. The presence of increased permeability of the small and large intestine may indicate the progression of the disease.
三糖试验评价自身免疫性肝病患者肠通透性
我们用三糖试验评价自身免疫性肝病患者的肠通透性。患者分为自身免疫性肝炎组、原发性胆管炎组和重叠综合征组(自身免疫性肝炎/原发性胆管炎)。102人被纳入横断面研究:72名自身免疫性肝病患者和30名健康志愿者。根据建议进行诊断- EASL (2017), AASLD (2019), IAIHG(2021)。以尿中乳果糖/甘露醇比值评价小肠通透性,以尿中三氯蔗糖水平(nmol/l)评价大肠通透性。采用高效液相色谱-质谱联用方法。自身免疫性肝病患者小肠通透性增高- 0.12 [0.07;0.234] (p < 0.001)与对照组- 0.013 [0.01;0.025]。大肠通透性- 760.8 [386.4;1640] nmol/l与对照组785.6 [408;1027.2]。自身免疫性肝病患者小肠通透性增高:肝炎分期- 0.17 [0.118];0.253] (p < 0.001),肝硬化- 0.106 [0.07];0.23] (p < 0.001)。肝炎和肝硬化患者的大肠通透性与对照组无显著差异。在自身免疫性肝炎患者中检测到三重糖试验值升高(小肠通透性增加[0,09],[0,07];[0,17] (p < 0.05),大肠通透性增加- 1091,2 [760;2352] (p < 0.05))和重叠综合征(小肠通透性增加- 0.18 [0,086;[0,3] (p < 0.05)和大肠通透性增加- 880 [424;[1680] (p < 0.05))。自身免疫性肝病患者表现为小肠通透性增加。小肠和大肠通透性增加可能表明疾病的进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
92358
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信